R
Rxsight Inc (RXST)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
$5.30
-0.02 (-0.38%)
Market Cap: $223.06M
Last updated: Nov 17, 2026 at 11:05 AM ET
Rxsight Inc (RXST) Valuation Multiples
Rxsight (RXST) trades at 1.8x sales and 0.9x book value. Its P/S of 1.8x is below its 5-year median of 7.9x. Its forward P/E is 116.3x.
Current Multiples
Its free cash flow yield is 8.4%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 116.3x |
| Price to sales | 1.8x |
| Price to book | 0.9x |
| Price to FCF | 11.9x |
| EV/FCF | 8.7x |
| PEG | N/A |
| FCF yield | 8.4% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.8x | 7.9x | N/A |
| P/B | 0.9x | 3.6x | N/A |
Valuation History
Over the 5 year ends shown, its P/S ranged from 3.2x in 2025 to 15.7x in 2023. 2025 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $10.42 | 3.2x | 1.6x |
| 2024 | $34.38 | 9.6x | 4.9x |
| 2023 | $40.32 | 15.7x | 9.0x |
| 2022 | $12.67 | 7.2x | 3.9x |
| 2021 | $11.25 | 5.6x | 2.2x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RXST
What is RXST's forward P/E ratio?
Rxsight has a forward P/E ratio of 116.3x.
Is RXST stock overvalued?
GNG's valuation label for RXST is Undervalued.
What is RXST's price to sales ratio?
Rxsight has a price to sales ratio of 1.8x.
RXST pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors